Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
13 janv. 2020 09h00 HE
|
Abeona Therapeutics Inc.
Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in...
Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24 déc. 2019 13h01 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten...
Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
09 déc. 2019 08h45 HE
|
Abeona Therapeutics Inc.
FDA removes clinical hold; Company may proceed with VIITAL™ study Company expects to initiate study in the first quarter of 2020 Primary endpoint confirmed as proportion of wounds with greater than...
Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates
12 nov. 2019 16h30 HE
|
Abeona Therapeutics Inc.
Submitted additional EB-101 transport stability data to FDA in response to Clinical Hold Letter; CMC clearance for pivotal VIITALTM Phase 3 trial anticipated in Q4 2019Publication of positive...
Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
10 mai 2019 16h15 HE
|
Abeona Therapeutics Inc.
CMC work completed in advance of EB-101 Phase 3 VITAL™ trial expected to begin mid-2019 IND submitted for ABO-202 in CLN1 disease Investor conference call on Tuesday, May 14 at 10:00 a.m. ET NEW...
Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
08 mai 2019 08h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data...
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
31 mai 2018 08h45 HE
|
Abeona Therapeutics Inc.
-- The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases -- Ribbon-cutting ceremony of gene and cell...
Abeona Therapeutics Announces Upcoming Presentations
08 mai 2018 08h15 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
29 janv. 2018 08h45 HE
|
Abeona Therapeutics Inc.
First gene therapy RMAT designation for Epidermolysis BullosaEnables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona...
Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
28 sept. 2017 08h32 HE
|
Abeona Therapeutics Inc
--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...